Amrutanjan Health Care cash flow

Latest FY26

Cash from operations: ₹36.0cr−29.3% on FY25
Capital spending: ₹55.0cr+54.7% on FY25
Free cash flow: −₹19.0cr₹15.3 cr in FY25
Cash from financing: −₹13.6cr−₹13.5 cr in FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Changes in working capital
Adjustments to reconcile profit — non-cash items						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	—	6.3	6.5	6.1	5.2
	—	0.2	0.2	0.1	0.1
	—	−15.9	−16.0	−14.8	−11.8
	—	−0.1	−0.0	0.1	0.2
	—	−0.9	1.1	0.2	0.4
	—	0.0	0.0	−0.2	−0.0
	—	−0.1	0.0	−0.0	0.0
	—	−10.1	1.6	−0.1	−2.8
	—	−5.7	−8.2	−17.0	4.8
	—	−0.5	−0.0	−0.0	−0.1
	—	0.0	0.0	0.1	0.0
	—	−9.0	0.0	−2.3	0.3
	—	0.0	−0.8	0.0	0.0
	—	2.9	14.6	9.5	−10.7
	—	0.0	0.1	−0.3	−3.6
	—	0.5	1.0	0.6	1.5
	—	0.9	0.3	2.1	0.5
	—	8.7	−0.8	−1.7	−2.3
Cash from operating activities
	72.7	77.9	69.1	61.9	53.6
	—	−22.9	−0.3	−17.5	−18.4
	—	55.0	68.8	44.4	35.3
	—	19.0	17.9	16.5	16.1
	—	36.0	50.9	27.9	19.2
Cash from investing activities
	—	55.0	35.6	6.7	8.9
	—	0.0	0.0	0.3	0.0
	—	0.1	0.0	0.0	0.0
	—	−20.8	11.5	−6.5	12.3
	—	−3.0	0.0	5.0	7.5
	—	15.9	16.0	14.1	11.2
	—	−21.2	−31.0	19.2	−2.5
Cash from financing activities
	—	0.1	0.2	1.2	0.0
	—	0.5	0.5	0.6	0.6
	—	13.2	13.3	13.4	13.4
	—	0.0	0.0	−35.5	0.0
	—	−13.6	−13.5	−48.3	−14.0
	—	1.1	6.4	−1.2	2.7
	—	1.1	6.4	−1.2	2.7
	—	—	—	3.7	2.7
Reference items
	73.5	75.7	58.2	51.2	44.4
	14.4%	15.1%	12.9%	12.2%	11.7%
	−19.0	−19.0	15.3	21.2	10.3
	−₹6.58	−₹6.58	₹5.31	₹7.33	₹3.56
	—	0.62×	1.00×	0.62×	0.48×
	—	19.0	17.9	16.5	16.1

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

alphave

AMRUTANJAN₹493.00

Amrutanjan Health Care Limited

· Pharma & Health

₹ CrorePeersJAGSNPHARM NGLFINE SIGACHI LINCOLN SYNCOMF THEMISMED HESTERBIOMcap ₹1,425 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation	5.2	6.1	6.5	6.3	—
+ Finance Costs	0.1	0.1	0.2	0.2	—
+ Interest Income	-11.8	-14.8	-16.0	-15.9	—
+ Fair Value (Gains) / Losses	0.2	0.1	-0.0	-0.1	—
+ Share-based Payments	0.4	0.2	1.1	-0.9	—
+ Other Non-cash Items	-0.0	-0.2	0.0	0.0	—
+ Other Reconciling Items	0.0	-0.0	0.0	-0.1	—
Changes in Working Capital
+ Inventories	-2.8	-0.1	1.6	-10.1	—
+ Trade Receivables — Current	4.8	-17.0	-8.2	-5.7	—
+ Other Financial Assets — Current	-0.1	-0.0	-0.0	-0.5	—
+ Other Financial Assets — Non-current	0.0	0.1	0.0	0.0	—
+ Other Current Assets	0.3	-2.3	0.0	-9.0	—
+ Other Non-current Assets	0.0	0.0	-0.8	0.0	—
+ Trade Payables — Current	-10.7	9.5	14.6	2.9	—
+ Other Financial Liabilities — Current	-3.6	-0.3	0.1	0.0	—
+ Other Current Liabilities	1.5	0.6	1.0	0.5	—
+ Provisions — Current	0.5	2.1	0.3	0.9	—
+ Provisions — Non-current	-2.3	-1.7	-0.8	8.7	—
Cash from Operating Activities
Profit Before Tax (per I/S)	53.6	61.9	69.1	77.9	72.7
+ Total Adjustments (incl. Working Capital)	-18.4	-17.5	-0.3	-22.9	—
Cash from Operations (pre-tax)	35.3	44.4	68.8	55.0	—
+ Income Taxes Paid	16.1	16.5	17.9	19.0	—
Cash from Operating Activities	19.2	27.9	50.9	36.0	—
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)	8.9	6.7	35.6	55.0	—
+ Disp of Fixed Assets	0.0	0.3	0.0	0.0	—
+ Disp of Investment Property	0.0	0.0	0.0	0.1	—
+ Purchase of Investments (Equity / Debt)	12.3	-6.5	11.5	-20.8	—
+ Sale of Investments (Equity / Debt)	7.5	5.0	0.0	-3.0	—
+ Interest Received — Investing	11.2	14.1	16.0	15.9	—
Cash from Investing Activities	-2.5	19.2	-31.0	-21.2	—
Cash from Financing Activities
+ Proceeds from Exercise of Stock Options	0.0	1.2	0.2	0.1	—
+ Payment of Lease Liabilities	0.6	0.6	0.5	0.5	—
+ Dividends Paid	13.4	13.4	13.3	13.2	—
+ Other Inflows / (Outflows) — Financing	0.0	-35.5	0.0	0.0	—
Cash from Financing Activities	-14.0	-48.3	-13.5	-13.6	—
Net Changes in Cash (pre-FX)	2.7	-1.2	6.4	1.1	—
Net Changes in Cash	2.7	-1.2	6.4	1.1	—
Closing Cash	2.7	3.7	—	—	—
Reference Items
EBITDA	44.4	51.2	58.2	75.7	73.5
EBITDA Margin %	11.69	12.16	12.88	15.06	14.37
Free Cash Flow (CFO − Capex)	10.3	21.2	15.3	-19.0	-19.0
Free Cash Flow per Basic Share	3.56	7.33	5.31	-6.58	-6.58
Cash Flow to Net Income	0.48	0.62	1.00	0.62	—
Cash Paid for Taxes	16.1	16.5	17.9	19.0	—

As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.